Recovery · Anti-inflammatory

KPV

KPV is a tripeptide (lysine-proline-valine) derived from alpha-melanocyte-stimulating hormone (α-MSH). Studied for inflammatory bowel disease, skin inflammation, and wound recovery.

Category: Recovery & Healing Last updated 2026-06-19

KPV at a glance

KPV is a tripeptide (lysine-proline-valine) derived from alpha-melanocyte-stimulating hormone (α-MSH). Studied for inflammatory bowel disease, skin inflammation, and wound recovery. Mechanism: α-MSH derived tripeptide. Typical route: Oral, subcutaneous, subjectal. FDA status: Not FDA-approved. Compounded by specialty pharmacies and sold by some peptide research suppliers.

Drug classα-MSH derived tripeptide

Half-lifeShort (rapid clearance)

RouteOral, subcutaneous, subjectal

Common dosing200-500 mcg/day

FDA statusNot approved

Available throughCompounding pharmacies

Mechanism of action

KPV exerts anti-inflammatory effects through multiple pathways, including suppression of NF-κB signaling, reduction of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and direct antibacterial activity. It is small enough to be absorbed orally with reasonable bioavailability.

Dosing reference

Oral: 200-500 mcg once or twice daily for gut applications. Subcutaneous: 250-500 mcg once daily. Topical formulations are also studied for inflammatory skin conditions.

Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.

FDA status & regulatory framework

Not FDA-approved. Compounded by specialty pharmacies and sold by some peptide research suppliers.

U.S. telehealth providers that work with KPV

#1 of 4

Defy Medical

88/100v3.0 six-pillar rubric

Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates KPV.

Read review →

#2 of 4

Marek Health

85/100v3.0 six-pillar rubric

Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates KPV.

Read review →

#3 of 4

Heally

70/100v3.0 six-pillar rubric

Starting at $110/mo. Heally is one of the providers covered in our editorial directory that dispenses or coordinates KPV.

Read review →

#4 of 4

PeterMD

71/100v3.0 six-pillar rubric

Starting at $125/mo. PeterMD is one of the providers covered in our editorial directory that dispenses or coordinates KPV.

Read review →

Related recovery peptides

Browse the full Recovery & Healing category →

Frequently asked questions about KPV

What is KPV used for?

KPV is most often used for inflammatory bowel conditions (IBD, IBS, ulcerative colitis), inflammatory skin conditions (psoriasis, eczema), and general anti-inflammatory support.

Can KPV be taken orally?

Yes. KPV is small enough to retain meaningful bioavailability when administered orally, which makes it a common choice for gut-targeted applications.

Lead Medical Researcher

Dr. Sam Saberian

Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.

Medical Reviewer

Alen A. Schwartz, MD

Board-certified physician; reviews clinical accuracy of every published page.

Edited by

Julliana Edwards

Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing